

Supplementary Table S2. PDX and patient clinical information

LuCaP	Date of Transplant	Tissue Implanted	CR subline establishment	Passage used	Age at Diagnosis	Gleason Score of Primary	Time with disease (Yr)	Androgen Ablation	CRPC	Patient Treatments
LuCaP 23.1	1991	LN Metastasis	2013	27	NA	NA	NA	NA	NA	NA
LuCaP 35	1993	LN Metastasis	2001	73	65	5+5	1	Y	Y	Lupron, Orchiectomy, Futamide, Cytozan, 5-FU
LuCaP 70	1997	Liver Metastasis	2011	21	59	3+4	5	Y	Y	Corticosteroids, DES, Strontium-89
LuCaP 73	1997	RRP	2011	13	47	4+5	1.9	Y	Y	Strontium-89, Ketoconazole, Corticosteroids, DES
LuCaP 77	1998	Femur Metastasis	2010	28	65	NA	15.4	Y	Y	Flutamide, Orchiectomy, Mitoxantrone, DES, XRT,
LuCaP 78	1998	LN Metastasis	2011	9	52	7	6.5	Y	Y	Taxotere, Ketoconazole, Corticosteroids, Mitoxantrone, DES
LuCaP 86.2	1999	Bladder Metastasis	2010	1	65	NA	14.1	Y	Y	Lupron, Flutamide
LuCaP 96	1999	TURP Rib Metastasis	1004	42	61	5+4	0.5	Y	N	Lupron, Biclutamide
LuCaP 105	2000		2010	18	48	5+3	5.1	Y	Y	Flutamide, Lupron, Taxotere, Ketoconazole, Mitoxantrone, Cytozan, 5-FU, Bisphosphonates
LuCaP 136	2004	Cells from Ascites Liver Metastasis	2012	17	62	5+5	0.6	Y	Y	Lupron, Casodex
LuCaP 147	2005		2010	25	67	4+5	2.2	Y	Y	Casodex, Lupron, XRT, DES, Taxotere, Ketoconazole, Corticosteroids, DES, Bisphosphonates
LuCaP 167	2012		2013	15	71	4+5	6.3	Y	Y	Casodex, Lupron, Dutasteride, Nilutamide, Ketoconazole, Corticosteroids, Abiraterone
LuCaP 176	2013	Rib Metastasis	2017	1	56	4+5	5.86	Y	Y	Lupron, Lupron + Casodex XRT, Corticosteroids, Abiraterone, Enzalutamide, etoposide

Note: Passage used = 1 when CR tumor was developed from fresh castration prior to the SPT study

Abbreviations:

TAN	Tissue acquisition necropsy
DES	Diethyl stilbestrol
LN	Lymph node
NA	Not available
OR	Operating room
RRP	Radical prostatectomy
TURP	Transurethral resection of prostate
XRT	Radiation